Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnabotulinumtoxinA for New Daily Persistent Headache
NCT01920945Phase 2Terminated
- Sponsor
- St. Luke's-Roosevelt Hospital Center
- Start
- Sep 2014
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in new daily persistent headache (NDPH), sponsored by St. Luke's-Roosevelt Hospital Center. Primary endpoint: Change from baseline in frequency of headache days at 29 weeks. Started Sep 2014; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
new daily persistent headache (NDPH)
Beyond the preview
Go deeper on NCT01920945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01920945.